Catchua
2021-11-05
Should buy more to keep?
Moderna Briefly Loses Top Spot on S&P 500 After Vaccine View<blockquote>Moderna因疫苗观点而短暂失去标普500榜首</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":846636879,"tweetId":"846636879","gmtCreate":1636076925251,"gmtModify":1636077283676,"author":{"id":3579261515703347,"idStr":"3579261515703347","authorId":3579261515703347,"authorIdStr":"3579261515703347","name":"Catchua","avatar":"https://static.tigerbbs.com/28615a1f839b67febc33928525f76b74","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Should buy more to keep?</p></body></html>","htmlText":"<html><head></head><body><p>Should buy more to keep?</p></body></html>","text":"Should buy more to keep?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846636879","repostId":1160687372,"repostType":4,"repost":{"id":"1160687372","kind":"news","pubTimestamp":1636076429,"share":"https://www.laohu8.com/m/news/1160687372?lang=zh_CN&edition=full","pubTime":"2021-11-05 09:40","market":"us","language":"en","title":"Moderna Briefly Loses Top Spot on S&P 500 After Vaccine View<blockquote>Moderna因疫苗观点而短暂失去标普500榜首</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160687372","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. plunged Thursday, briefly losing its place as the best performing stock ","content":"<p>(Bloomberg) -- Moderna Inc. plunged Thursday, briefly losing its place as the best performing stock on the S&P 500 Index.</p><p><blockquote>（彭博社）——Moderna Inc.周四暴跌，短暂失去了标普500指数表现最佳股票的地位。</blockquote></p><p> The biotech’s stock closed down 18%, the biggest daily drop since March 2020, after a weakened outlook for its Covid-19 vaccine and sales that missed the average analyst estimate. For a few minutes the vaccine maker was supplanted by shale oil producer Devon Energy Corp., before finishing the day back in the lead.</p><p><blockquote>该生物技术公司的股价收盘下跌18%，创2020年3月以来的最大单日跌幅，此前其Covid-19疫苗前景疲软，销售额低于分析师平均预期。这家疫苗制造商在几分钟内被页岩油生产商德文能源公司取代，然后在当天结束时重新领先。</blockquote></p><p> The U.K.’s approval of Merck & Co.’s Covid-19 antiviral pill also hit Moderna’s shares. British regulators described the treatment as safe and effective and more authorizations could hurt the sales of Covid vaccines.</p><p><blockquote>英国批准默克公司的Covid-19抗病毒药物也打击了Moderna的股价。英国监管机构称这种治疗方法安全有效，更多授权可能会损害新冠疫苗的销售。</blockquote></p><p> The drugmaker’s meteoric rally earlier this year led to its addition into the benchmark S&P 500 in July after its coronavirus inoculation received emergency authorization in the U.S. in December, a week behind the first approval for Pfizer Inc. and BioNTech SE’s vaccine. But concerns about the future sales have weighed on the shares. Moderna has slumped more than 40% since a peak in August.</p><p><blockquote>该制药商今年早些时候的飞速上涨导致其冠状病毒疫苗于12月在美国获得紧急授权，比辉瑞公司和BioNTech SE的疫苗首次获得批准晚了一周，并于7月被纳入基准标普500。但对未来销售的担忧令股价承压。自8月份达到峰值以来，Moderna股价已下跌超过40%。</blockquote></p><p> “Shares remain substantially overvalued,” wrote SVB Leerink analyst Mani Foroohar in a research note. The market for Covid vaccines is transitioning to “a much smaller, much more competitive chronic endemic market,” he added.</p><p><blockquote>SVB Leerink分析师Mani Foroohar在一份研究报告中写道：“股价仍然被严重高估。”他补充说，Covid疫苗市场正在向“一个更小、竞争更激烈的慢性地方病市场”过渡。</blockquote></p><p> Ten analysts covering Moderna have either a hold or sell recommendation with only seven suggesting investors buy the stock, data compiled by Bloomberg show. Its shares are still up roughly 172% this year.</p><p><blockquote>彭博社汇编的数据显示，研究Moderna的10名分析师给予持有或卖出建议，只有7名分析师建议投资者购买该股。其股价今年仍上涨约172%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Briefly Loses Top Spot on S&P 500 After Vaccine View<blockquote>Moderna因疫苗观点而短暂失去标普500榜首</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Briefly Loses Top Spot on S&P 500 After Vaccine View<blockquote>Moderna因疫苗观点而短暂失去标普500榜首</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-05 09:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Moderna Inc. plunged Thursday, briefly losing its place as the best performing stock on the S&P 500 Index.</p><p><blockquote>（彭博社）——Moderna Inc.周四暴跌，短暂失去了标普500指数表现最佳股票的地位。</blockquote></p><p> The biotech’s stock closed down 18%, the biggest daily drop since March 2020, after a weakened outlook for its Covid-19 vaccine and sales that missed the average analyst estimate. For a few minutes the vaccine maker was supplanted by shale oil producer Devon Energy Corp., before finishing the day back in the lead.</p><p><blockquote>该生物技术公司的股价收盘下跌18%，创2020年3月以来的最大单日跌幅，此前其Covid-19疫苗前景疲软，销售额低于分析师平均预期。这家疫苗制造商在几分钟内被页岩油生产商德文能源公司取代，然后在当天结束时重新领先。</blockquote></p><p> The U.K.’s approval of Merck & Co.’s Covid-19 antiviral pill also hit Moderna’s shares. British regulators described the treatment as safe and effective and more authorizations could hurt the sales of Covid vaccines.</p><p><blockquote>英国批准默克公司的Covid-19抗病毒药物也打击了Moderna的股价。英国监管机构称这种治疗方法安全有效，更多授权可能会损害新冠疫苗的销售。</blockquote></p><p> The drugmaker’s meteoric rally earlier this year led to its addition into the benchmark S&P 500 in July after its coronavirus inoculation received emergency authorization in the U.S. in December, a week behind the first approval for Pfizer Inc. and BioNTech SE’s vaccine. But concerns about the future sales have weighed on the shares. Moderna has slumped more than 40% since a peak in August.</p><p><blockquote>该制药商今年早些时候的飞速上涨导致其冠状病毒疫苗于12月在美国获得紧急授权，比辉瑞公司和BioNTech SE的疫苗首次获得批准晚了一周，并于7月被纳入基准标普500。但对未来销售的担忧令股价承压。自8月份达到峰值以来，Moderna股价已下跌超过40%。</blockquote></p><p> “Shares remain substantially overvalued,” wrote SVB Leerink analyst Mani Foroohar in a research note. The market for Covid vaccines is transitioning to “a much smaller, much more competitive chronic endemic market,” he added.</p><p><blockquote>SVB Leerink分析师Mani Foroohar在一份研究报告中写道：“股价仍然被严重高估。”他补充说，Covid疫苗市场正在向“一个更小、竞争更激烈的慢性地方病市场”过渡。</blockquote></p><p> Ten analysts covering Moderna have either a hold or sell recommendation with only seven suggesting investors buy the stock, data compiled by Bloomberg show. Its shares are still up roughly 172% this year.</p><p><blockquote>彭博社汇编的数据显示，研究Moderna的10名分析师给予持有或卖出建议，只有7名分析师建议投资者购买该股。其股价今年仍上涨约172%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/moderna-loses-top-spot-p-173130001.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-loses-top-spot-p-173130001.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160687372","content_text":"(Bloomberg) -- Moderna Inc. plunged Thursday, briefly losing its place as the best performing stock on the S&P 500 Index.\nThe biotech’s stock closed down 18%, the biggest daily drop since March 2020, after a weakened outlook for its Covid-19 vaccine and sales that missed the average analyst estimate. For a few minutes the vaccine maker was supplanted by shale oil producer Devon Energy Corp., before finishing the day back in the lead.\nThe U.K.’s approval of Merck & Co.’s Covid-19 antiviral pill also hit Moderna’s shares. British regulators described the treatment as safe and effective and more authorizations could hurt the sales of Covid vaccines.\nThe drugmaker’s meteoric rally earlier this year led to its addition into the benchmark S&P 500 in July after its coronavirus inoculation received emergency authorization in the U.S. in December, a week behind the first approval for Pfizer Inc. and BioNTech SE’s vaccine. But concerns about the future sales have weighed on the shares. Moderna has slumped more than 40% since a peak in August.\n“Shares remain substantially overvalued,” wrote SVB Leerink analyst Mani Foroohar in a research note. The market for Covid vaccines is transitioning to “a much smaller, much more competitive chronic endemic market,” he added.\nTen analysts covering Moderna have either a hold or sell recommendation with only seven suggesting investors buy the stock, data compiled by Bloomberg show. Its shares are still up roughly 172% this year.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":553,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/846636879"}
精彩评论